Abstract
Purpose
In the past, anomalous estrogen receptor (ER) regulation has been associated with various lung pathologies, but so far its involvement in lung cancer initiation and/or progression has remained unclear. Here, we aimed at assessing in vivo and in vitro ER expression and its possible epigenetic regulation in non-small cell lung cancer (NSCLC) samples and their corresponding normal tissues and cells.
Methods
ERα and ERβ gene expression levels were assessed using real time quantitative PCR (RT-qPCR), whereas ERα and ERβ gene promoter methylation levels were assessed using DNA bisulfite conversion followed by pyrosequencing. We included NSCLC (n = 87) and adjacent histologically normal lung tissue samples from lung cancer patients (n = 184), primary normal bronchial epithelial-derived cell cultures (n = 11), immortalized bronchial epithelial-derived cell lines (n = 3) and NSCLC derived cell lines (n = 9).
Results
Using RT-qPCR we found significantly lower ERα and ERβ expression levels in the NSCLC tissue samples compared to their normal adjacent tissue samples. These lower ER expression levels were confirmed in vitro using primary normal bronchial epithelial-derived cell cultures, immortalized bronchial epithelial-derived cell lines and NSCLC-derived cell lines. By using this latter panel of cells, we found that ER gene promoter hypermethylation was associated with decreased ER expression. In addition we found that in tumor and normal lung tissues, smoking was associated with decreased ER expression and that normal lung tissues with a low ERβ expression level exhibited increased smoking-related DNA adducts.
Conclusions
Taken together, our results indicate that decreased ER expression mediated by DNA methylation may play a role in NSCLC development.
References
E. A. Musgrove, R. L. Sutherland, Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9, 631–643 (2009)
L. P. Stabile, S. Dacic, S. R. Land, D. E. Lenzner, R. Dhir, M. Acquafondata, R. J. Landreneau, J. R. Grandis, J. M. Siegfried, Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res 17, 154–164 (2011)
A. H. Wu, B. E. Henderson, M. C. Pike, M. C. Yu, Smoking and other risk factors for lung cancer in women. J Natl Cancer Inst 74, 747–751 (1985)
D. J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, R. M. Evans, The nuclear receptor superfamily: the second decade. Cell 83, 835–839 (1995)
G. Early, Breast Cancer Trialists’ Collaborative, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(1687–1717) (2005)
V. Kirn, R. Shi, S. Heublein, J. Knabl, M. Guenthner-Biller, U. Andergassen, C. Fridrich, W. Malter, J. Harder, K. Friese, D. Mayr, U. Jeschke, Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients. J Cancer Res Clin Oncol 140, 1681–1687 (2014)
S. Mishra, Q. Tai, X. Gu, J. Schmitz, A. Poullard, R. J. Fajardo, D. Mahalingam, X. Chen, X. Zhu, L. Z. Sun, Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget 6, 44388–44402 (2015)
R. Kennelly, D. O. Kavanagh, A. M. Hogan, D. C. Winter, Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 9, 385–391 (2008)
D. C. Marquez-Garban, H. W. Chen, M. C. Fishbein, L. Goodglick, R. J. Pietras, Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72, 135–143 (2007)
L. P. Stabile, A. L. Davis, C. T. Gubish, T. M. Hopkins, J. D. Luketich, N. Christie, S. Finkelstein, J. M. Siegfried, Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62, 2141–2150 (2002)
H. Kawai, A. Ishii, K. Washiya, T. Konno, H. Kon, C. Yamaya, I. Ono, Y. Minamiya, J. Ogawa, Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11, 5084–5089 (2005)
M. J. Fasco, G. J. Hurteau, S. D. Spivack, Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 188, 125–140 (2002)
S. Mollerup, K. Jorgensen, G. Berge, A. Haugen, Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37, 153–159 (2002)
L. Di Nunno, L. G. Larsson, J. J. Rinehart, R. S. Beissner, Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 124, 1467–1470 (2000)
A. G. Schwartz, G. M. Prysak, V. Murphy, F. Lonardo, H. Pass, J. Schwartz, S. Brooks, Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 11, 7280–7287 (2005)
C. Thomas, J. A. Gustafsson, The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11, 597–608 (2011)
S. A. Belinsky, S. S. Snow, K. J. Nikula, G. L. Finch, C. S. Tellez, W. A. Palmisano, Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens. Carcinogenesis 23, 335–339 (2002)
M. Esteller, D. N. A. Aberrant, Methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicology 45, 629–656 (2005)
J. P. Issa, B. A. Zehnbauer, C. I. Civin, M. I. Collector, S. J. Sharkis, N. E. Davidson, S. H. Kaufmann, S. B. Baylin, The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 56, 973–977 (1996)
J. F. Lechner, A. Haugen, I. A. McClendon, E. W. Pettis, Clonal growth of normal adult human bronchial epithelial cells in a serum-free medium. In Vitro 18, 633–642 (1982)
R. D. Ramirez, S. Sheridan, L. Girard, M. Sato, Y. Kim, J. Pollack, M. Peyton, Y. Zou, J. M. Kurie, J. M. Dimaio, S. Milchgrub, A. L. Smith, R. F. Souza, L. Gilbey, X. Zhang, K. Gandia, M. B. Vaughan, W. E. Wright, A. F. Gazdar, J. W. Shay, J. D. Minna, Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64, 9027–9034 (2004)
H. K. Oie, E. K. Russell, D. N. Carney, A. F. Gazdar, Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl 24, 24–31 (1996)
S. E. Olivo-Marston, L. E. Mechanic, S. Mollerup, E. D. Bowman, A. T. Remaley, M. R. Forman, V. Skaug, Y. L. Zheng, A. Haugen, C. C. Harris, Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis 31 (1778–1786)
X. Tekpli, S. Zienolddiny, V. Skaug, L. Stangeland, A. Haugen, S. Mollerup, DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int J Cancer 131, 1509–1516 (2012)
Z. Birsu Cincin, M. Unlu, B. Kiran, E. Sinem Bireller, Y. Baran, B. Cakmakoglu, Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cell Oncol 38(195–204) (2015)
A. Koren, E. Sodja, M. Rijavec, M. Jez, V. Kovac, P. Korosec, T. Cufer, Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients. Cell Oncol 38(387–395) (2015)
C. Zeng, W. Fan, X. Zhang, RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report. Cell. Oncol 38(319–325) (2015)
D. Nojima, L. C. Li, A. Dharia, G. Perinchery, L. Ribeiro-Filho, T. S. Yen, R. Dahiya, CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 92, 2076–2083 (2001)
C. Zhao, E. W. Lam, A. Sunters, E. Enmark, M. T. De Bella, R. C. Coombes, J. A. Gustafsson, K. Dahlman-Wright, Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22, 7600–7606 (2003)
F. Suzuki, J. Akahira, I. Miura, T. Suzuki, K. Ito, S. Hayashi, H. Sasano, N. Yaegashi, Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5′-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99, 2365–2372 (2008)
X. Zhang, Y. K. Leung, S. M. Ho, AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0 N promoter in prostate cancer cells. Oncogene 26, 7346–7354 (2007)
N. D. Freedman, M. F. Leitzmann, A. R. Hollenbeck, A. Schatzkin, C. C. Abnet, Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 9, 649–656 (2008)
D. H. Phillips, A. Hewer, C. N. Martin, R. C. Garner, M. M. King, Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336, 790–792 (1988)
M. G. Raso, C. Behrens, M. H. Herynk, S. Liu, L. Prudkin, N. C. Ozburn, D. M. Woods, X. Tang, R. J. Mehran, C. Moran, J. J. Lee, I. I. Wistuba, Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15, 5359–5368 (2009)
A. Kerr, 2nd, J. F. Eliason, J. L. Wittliff, Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. Adv Exp Med Biol 617, 377–384 (2008)
J. A. Baron, Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br Med Bull 52, 58–73 (1996)
X. Z. Zhao, Y. Liu, L. J. Zhou, Z. Q. Wang, Z. H. Wu, X. Y. Yang, Role of estrogen in lung cancer based on the estrogen receptor-epithelial mesenchymal transduction signaling pathways. Onco Targets Ther 8, 2849–2863 (2015)
S. A. Belinsky, Unmasking the lung cancer epigenome. Annu Rev Physiol 77, 453–474 (2015)
S. J. Ellem, G. P. Risbridger, Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 7, 621–627 (2007)
A. M. Traynor, J. H. Schiller, L. P. Stabile, J. M. Kolesar, J. C. Eickhoff, S. Dacic, T. Hoang, S. Dubey, S. M. Marcotte, J. M. Siegfried, Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64, 51–59 (2009)
H. Niikawa, T. Suzuki, Y. Miki, S. Suzuki, S. Nagasaki, J. Akahira, S. Honma, D. B. Evans, S. Hayashi, T. Kondo, H. Sasano, Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14, 4417–4426 (2008)
G. Maillot, M. Lacroix-Triki, S. Pierredon, L. Gratadou, S. Schmidt, V. Benes, H. Roche, F. Dalenc, D. Auboeuf, S. Millevoi, S. Vagner, Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 69, 8332–8340 (2009)
X. Yu, X. Zhang, I. B. Dhakal, M. Beggs, S. Kadlubar, D. Luo, Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer 12, 29 (2012)
E. Prodromaki, A. Korpetinou, E. Giannopoulou, E. Vlotinou, M. Chatziathanasiadou, N. I. Papachristou, C. D. scopa, H. Papadaki, H. P. Kalofonos, D. J. Papachristou, Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas. Cell Oncol 38, 307–317 (2015)
Acknowledgments
This study was supported by grants from the Norwegian Cancer Society. We are grateful to Mrs. Tove Andreassen and Mrs. Elin Einarsdottir Thorner for excellent technical assistance. The authors gratefully acknowledge collaboration of Dr. Lodve Stangeland, Haukeland University Hospital, Bergen, for recruiting the lung cancer patients and collecting the tissue specimens.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Electronic supplementary material
Supplementary Figure 1
ER expression detailed for each individual cell line a-b: ERα and ERβ gene expression was analyzed in 11 primary cultured human lung cells (NHBE), 3 immortalized human bronchial epithelial cell lines (HBEC), and 9 human lung adenocarcinoma cell lines (HLAC). (PPTX 225 kb)
Supplementary Figure 2
Schematic representation of the location of the different assays designed to study (a) ERα and (b) ERβ promoter DNA methylation. (PPTX 47 kb)
Supplementary Figure 3
DNA methylation of ER promoters detailed for each individual cell line: DNA methylation levels were obtained by analyzing the mean methylation of all the CpG sites present in the different regions of ERα (a) or ERβ (b) promoters. We used 11 primary cultured human lung cells (NHBE), 3 immortalized human bronchial epithelial cell lines (HBEC), and 9 human lung adenocarcinoma cell lines (HLAC). (PPTX 75 kb)
Supplementary Figure 4
Effect of AZA on ERs expression detailed for each individual cell line: a-b: AZA effects on ER expression in human lung cultured cells. Cells were exposed or not for 5 days during proliferation phase to the demethylating agent AZA (0.5 μm). Expression of ER mRNA was normalized to β-actin mRNA levels. AZA effects on gene expression are presented as fold induction of gene expression induced by AZA. (PPTX 72 kb)
Supplementary Table 1
(DOCX 14 kb)
Supplementary Table 2
(DOCX 16 kb)
Rights and permissions
About this article
Cite this article
Tekpli, X., Skaug, V., Bæra, R. et al. Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report. Cell Oncol. 39, 583–589 (2016). https://doi.org/10.1007/s13402-016-0295-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-016-0295-3